APO RESEARCH · REPORT
Microbiome Drugs
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.
Product & engineering
Understand the product.
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.
Selected research
Market Structure
Global Microbiome Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.
North America and Europe hold most of market share of microbiome drugs, and North America occupies a share over 77%, on the other hand, Europe takes a share of over 22% in total. Global core microbiome drugs manufacturers include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics etc.
Report Includes
Read the full market overview
This report provides an overview of the global Microbiome Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Microbiome Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Microbiome Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Microbiome Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Microbiome Drugs Segment by Company
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
Rebiotix
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Osel
Microbiome Drugs Segment by Type
Oral Dosage Form
Enteric Capsules
Microbiome Drugs Segment by Symptom
Gastrointestinal Disorders
Autoimmune Disorders
Diabetes
Cancer
Others
Microbiome Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Microbiome Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Microbiome Drugs industry.
Chapter 3: Detailed analysis of Microbiome Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbiome Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Dosage Form
- Enteric Capsules
Applications
- Gastrointestinal Disorders
- Autoimmune Disorders
- Diabetes
- Cancer
- Others
Companies covered
- Seres Therapeutics
- Assembly Biosciences
- Synthetic Biologics
- Interxon
- PureTech
- Synlogic
- Enterome BioScience
- 4D Pharma
- Second Genome
- AOBiome
- Rebiotix
- Metabiomics
- Ritter Pharmaceuticals
- Symberix
- OpenBiome
- Azitra
- Osel
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Microbiome Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Oral Dosage Form
- 1.2.3 Enteric Capsules
- 1.3 Market Analysis by Application
- 1.3.1 Global Microbiome Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Gastrointestinal Disorders
- 1.3.3 Autoimmune Disorders
- 1.3.4 Diabetes
- 1.3.5 Cancer
- 1.3.6 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Microbiome Drugs Growth Trends by Region
- 1.5.1 Global Microbiome Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Microbiome Drugs Market Size by Region (2021-2026)
- 1.5.3 Microbiome Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Microbiome Drugs Market Dynamics
- 2.1 Microbiome Drugs Industry Trends
- 2.2 Microbiome Drugs Industry Drivers
- 2.3 Microbiome Drugs Industry Opportunities and Challenges
- 2.4 Microbiome Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Microbiome Drugs Revenue by Company (2021-2026)
- 3.2 Global Microbiome Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Microbiome Drugs Key Company Head office and Area Served
- 3.4 Global Microbiome Drugs Company, Product Type & Application
- 3.5 Global Microbiome Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Microbiome Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Microbiome Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Microbiome Drugs Tier 1, Tier 2, and Tier 3
4 Microbiome Drugs Market by Type
- 4.1 Global Microbiome Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Microbiome Drugs Market Size by Type (2021-2032)
- 4.3 Global Microbiome Drugs Market Size Share by Type (2021-2032)
5 Microbiome Drugs Market by Application
- 5.1 Global Microbiome Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Microbiome Drugs Market Size by Application (2021-2032)
- 5.3 Global Microbiome Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Seres Therapeutics
- 6.1.1 Seres Therapeutics Company Information
- 6.1.2 Seres Therapeutics Business Overview
- 6.1.3 Seres Therapeutics Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Seres Therapeutics Microbiome Drugs Product Portfolio
- 6.1.5 Seres Therapeutics Recent Developments
- 6.2 Assembly Biosciences
- 6.2.1 Assembly Biosciences Company Information
- 6.2.2 Assembly Biosciences Business Overview
- 6.2.3 Assembly Biosciences Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Assembly Biosciences Microbiome Drugs Product Portfolio
- 6.2.5 Assembly Biosciences Recent Developments
- 6.3 Synthetic Biologics
- 6.3.1 Synthetic Biologics Company Information
- 6.3.2 Synthetic Biologics Business Overview
- 6.3.3 Synthetic Biologics Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Synthetic Biologics Microbiome Drugs Product Portfolio
- 6.3.5 Synthetic Biologics Recent Developments
- 6.4 Interxon
- 6.4.1 Interxon Company Information
- 6.4.2 Interxon Business Overview
- 6.4.3 Interxon Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Interxon Microbiome Drugs Product Portfolio
- 6.4.5 Interxon Recent Developments
- 6.5 PureTech
- 6.5.1 PureTech Company Information
- 6.5.2 PureTech Business Overview
- 6.5.3 PureTech Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 PureTech Microbiome Drugs Product Portfolio
- 6.5.5 PureTech Recent Developments
- 6.6 Synlogic
- 6.6.1 Synlogic Company Information
- 6.6.2 Synlogic Business Overview
- 6.6.3 Synlogic Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Synlogic Microbiome Drugs Product Portfolio
- 6.6.5 Synlogic Recent Developments
- 6.7 Enterome BioScience
- 6.7.1 Enterome BioScience Company Information
- 6.7.2 Enterome BioScience Business Overview
- 6.7.3 Enterome BioScience Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Enterome BioScience Microbiome Drugs Product Portfolio
- 6.7.5 Enterome BioScience Recent Developments
- 6.8 4D Pharma
- 6.8.1 4D Pharma Company Information
- 6.8.2 4D Pharma Business Overview
- 6.8.3 4D Pharma Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 4D Pharma Microbiome Drugs Product Portfolio
- 6.8.5 4D Pharma Recent Developments
- 6.9 Second Genome
- 6.9.1 Second Genome Company Information
- 6.9.2 Second Genome Business Overview
- 6.9.3 Second Genome Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Second Genome Microbiome Drugs Product Portfolio
- 6.9.5 Second Genome Recent Developments
- 6.10 AOBiome
- 6.10.1 AOBiome Company Information
- 6.10.2 AOBiome Business Overview
- 6.10.3 AOBiome Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 AOBiome Microbiome Drugs Product Portfolio
- 6.10.5 AOBiome Recent Developments
- 6.11 Rebiotix
- 6.11.1 Rebiotix Company Information
- 6.11.2 Rebiotix Business Overview
- 6.11.3 Rebiotix Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Rebiotix Microbiome Drugs Product Portfolio
- 6.11.5 Rebiotix Recent Developments
- 6.12 Metabiomics
- 6.12.1 Metabiomics Company Information
- 6.12.2 Metabiomics Business Overview
- 6.12.3 Metabiomics Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Metabiomics Microbiome Drugs Product Portfolio
- 6.12.5 Metabiomics Recent Developments
- 6.13 Ritter Pharmaceuticals
- 6.13.1 Ritter Pharmaceuticals Company Information
- 6.13.2 Ritter Pharmaceuticals Business Overview
- 6.13.3 Ritter Pharmaceuticals Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Ritter Pharmaceuticals Microbiome Drugs Product Portfolio
- 6.13.5 Ritter Pharmaceuticals Recent Developments
- 6.14 Symberix
- 6.14.1 Symberix Company Information
- 6.14.2 Symberix Business Overview
- 6.14.3 Symberix Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Symberix Microbiome Drugs Product Portfolio
- 6.14.5 Symberix Recent Developments
- 6.15 OpenBiome
- 6.15.1 OpenBiome Company Information
- 6.15.2 OpenBiome Business Overview
- 6.15.3 OpenBiome Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 OpenBiome Microbiome Drugs Product Portfolio
- 6.15.5 OpenBiome Recent Developments
- 6.16 Azitra
- 6.16.1 Azitra Company Information
- 6.16.2 Azitra Business Overview
- 6.16.3 Azitra Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Azitra Microbiome Drugs Product Portfolio
- 6.16.5 Azitra Recent Developments
- 6.17 Osel
- 6.17.1 Osel Company Information
- 6.17.2 Osel Business Overview
- 6.17.3 Osel Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 Osel Microbiome Drugs Product Portfolio
- 6.17.5 Osel Recent Developments
7 North America
- 7.1 North America Microbiome Drugs Market Size (2021-2032)
- 7.2 North America Microbiome Drugs Market Size by Type
- 7.2.1 North America Microbiome Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Microbiome Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Microbiome Drugs Market Share by Type (2021-2032)
- 7.3 North America Microbiome Drugs Market Size by Application
- 7.3.1 North America Microbiome Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Microbiome Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Microbiome Drugs Market Share by Application (2021-2032)
- 7.4 North America Microbiome Drugs Market Size by Country
- 7.4.1 North America Microbiome Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Microbiome Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Microbiome Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Microbiome Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Microbiome Drugs Market Size (2021-2032)
- 8.2 Europe Microbiome Drugs Market Size by Type
- 8.2.1 Europe Microbiome Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Microbiome Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Microbiome Drugs Market Share by Type (2021-2032)
- 8.3 Europe Microbiome Drugs Market Size by Application
- 8.3.1 Europe Microbiome Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Microbiome Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Microbiome Drugs Market Share by Application (2021-2032)
- 8.4 Europe Microbiome Drugs Market Size by Country
- 8.4.1 Europe Microbiome Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Microbiome Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Microbiome Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Microbiome Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Microbiome Drugs Market Size (2021-2032)
- 9.2 China Microbiome Drugs Market Size by Type
- 9.2.1 China Microbiome Drugs Market Size by Type (2021-2026)
- 9.2.2 China Microbiome Drugs Market Size by Type (2027-2032)
- 9.2.3 China Microbiome Drugs Market Share by Type (2021-2032)
- 9.3 China Microbiome Drugs Market Size by Application
- 9.3.1 China Microbiome Drugs Market Size by Application (2021-2026)
- 9.3.2 China Microbiome Drugs Market Size by Application (2027-2032)
- 9.3.3 China Microbiome Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Microbiome Drugs Market Size (2021-2032)
- 10.2 Asia Microbiome Drugs Market Size by Type
- 10.2.1 Asia Microbiome Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Microbiome Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Microbiome Drugs Market Share by Type (2021-2032)
- 10.3 Asia Microbiome Drugs Market Size by Application
- 10.3.1 Asia Microbiome Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Microbiome Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Microbiome Drugs Market Share by Application (2021-2032)
- 10.4 Asia Microbiome Drugs Market Size by Country
- 10.4.1 Asia Microbiome Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Microbiome Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Microbiome Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Microbiome Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Microbiome Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Microbiome Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Microbiome Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Microbiome Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Microbiome Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Microbiome Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Microbiome Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Microbiome Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Microbiome Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Microbiome Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Microbiome Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Microbiome Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Microbiome Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Microbiome Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst